NCT07135167View on ClinicalTrials.gov

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Down Syndrome (DS)KeratoconusPellucid Marginal DegenerationForme Fruste Keratoconus (FFK)
Interventions
COMBINATION_PRODUCT

Epi-ON corneal cross-linking (CXL)

"Corneal cross-linking involves the following steps:~* applying riboflavin (Vitamin B2 eye drops) to the eye, then~* exposing the eye to ultraviolet (UV-A) light for 20 minutes."

Sponsors
All Listed Sponsors
lead

Clinical Research Consultants, Inc.

INDUSTRY

NCT07135167 - Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome | Biotech Hunter | Biotech Hunter